bimekizumab
ucb pharmaceuticals
['be complete', 'bimekizumab', ' psa', '#1599']
be complete study:
bimekizumab (il-17a and il-17f inhibitor) efficacious in phase 3 trial for treatment of psa. no new safety signals. abs#1599 #acr22 
Rheumatologist. Amateur chef. YNWA. Views and opinions are my own.